JP7555826B2 - 新規構造成分を含有するナノ粒子ワクチン - Google Patents

新規構造成分を含有するナノ粒子ワクチン Download PDF

Info

Publication number
JP7555826B2
JP7555826B2 JP2020568685A JP2020568685A JP7555826B2 JP 7555826 B2 JP7555826 B2 JP 7555826B2 JP 2020568685 A JP2020568685 A JP 2020568685A JP 2020568685 A JP2020568685 A JP 2020568685A JP 7555826 B2 JP7555826 B2 JP 7555826B2
Authority
JP
Japan
Prior art keywords
nanoparticle
subunit
vaccine composition
seq
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020568685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527077A (ja
JP2021527077A5 (cg-RX-API-DMAC7.html
Inventor
ホー,リンリン
ジュー,ジャン
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2021527077A publication Critical patent/JP2021527077A/ja
Publication of JP2021527077A5 publication Critical patent/JP2021527077A5/ja
Application granted granted Critical
Publication of JP7555826B2 publication Critical patent/JP7555826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
JP2020568685A 2018-06-13 2019-06-13 新規構造成分を含有するナノ粒子ワクチン Active JP7555826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684229P 2018-06-13 2018-06-13
US62/684,229 2018-06-13
PCT/US2019/036917 WO2019241483A1 (en) 2018-06-13 2019-06-13 Nanoparticle vaccines with novel structural components

Publications (3)

Publication Number Publication Date
JP2021527077A JP2021527077A (ja) 2021-10-11
JP2021527077A5 JP2021527077A5 (cg-RX-API-DMAC7.html) 2022-06-20
JP7555826B2 true JP7555826B2 (ja) 2024-09-25

Family

ID=68843607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568685A Active JP7555826B2 (ja) 2018-06-13 2019-06-13 新規構造成分を含有するナノ粒子ワクチン

Country Status (12)

Country Link
US (2) US11097002B2 (cg-RX-API-DMAC7.html)
EP (1) EP3807210A4 (cg-RX-API-DMAC7.html)
JP (1) JP7555826B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210021530A (cg-RX-API-DMAC7.html)
CN (1) CN112469661B (cg-RX-API-DMAC7.html)
AU (1) AU2019285048B2 (cg-RX-API-DMAC7.html)
CA (1) CA3103460A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092808A1 (cg-RX-API-DMAC7.html)
IL (1) IL279351B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202012313PA (cg-RX-API-DMAC7.html)
WO (1) WO2019241483A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100032B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL274130B2 (en) * 2017-11-01 2025-08-01 Scripps Research Inst Novel scaffolded hiv-1 vaccine immunogens
EP4003513A4 (en) * 2019-07-26 2023-08-30 The Scripps Research Institute MODIFIED HCV E2 IMMUNOGENS AND ASSOCIATED VACCINE COMPOSITIONS
CN115515627A (zh) * 2020-02-11 2022-12-23 美国政府(由卫生和人类服务部的部长所代表) SARS-CoV-2疫苗
KR20220142471A (ko) * 2020-02-14 2022-10-21 유니버시티 오브 워싱턴 폴리펩타이드 및 그 용도
CN113121704B (zh) * 2020-03-25 2023-04-07 昆山新蕴达生物科技有限公司 基于纳米颗粒的冠状病毒疫苗
US11278617B2 (en) 2020-03-31 2022-03-22 Engimata, Inc Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
CN112023035A (zh) * 2020-04-07 2020-12-04 中国医学科学院医学生物学研究所 一种以SARS-CoV-2病毒S蛋白RBD区为抗原的纳米疫苗及其制备
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20205382A1 (en) * 2020-04-09 2021-05-07 Niemelae Erik Method for preventing the spreading and lowering the infection rate of pathogens
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US11192940B2 (en) 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
US20230149535A1 (en) * 2020-04-11 2023-05-18 The Wistar Institute Of Anatomy & Biology Vaccines for coronavirus and methods of using the same
WO2021210984A1 (en) * 2020-04-17 2021-10-21 Erasmus University Medical Center Rotterdam Coronavirus vaccine
KR20220153767A (ko) * 2021-05-12 2022-11-21 (주)인테라 엔캡슐린 기반 뎅기 바이러스 또는 코로나 바이러스 백신 생산을 위한 재조합 발현 벡터 및 이의 제조방법
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
US20210403509A1 (en) * 2020-06-24 2021-12-30 Avalon GloboCare Corp. S-layer vaccine fusion proteins and methods of use
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
IL300527A (en) * 2020-08-10 2023-04-01 Scripps Research Inst COMPOSITIONS AND METHODS RELATED TO EBOLA VIRUS VACCINES
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
IL302645A (en) * 2020-11-03 2023-07-01 The Wistrar Inst Of Anatomy And Biology Dna encoded nanoparticles and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine
CN114230674B (zh) * 2020-12-01 2023-09-26 中国医学科学院基础医学研究所 一种含Fc结构域的新型冠状病毒S蛋白受体结合域融合蛋白及其用途
WO2022133259A2 (en) * 2020-12-18 2022-06-23 The Scripps Research Institute Immunogenic compositions
EP4263576A4 (en) * 2020-12-18 2025-08-13 Scripps Research Inst IMMUNOGENIC COMPOSITIONS
EP4291569A4 (en) * 2021-02-10 2025-03-26 Duke University CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS OF USE THEREOF
CN112979826B (zh) * 2021-03-03 2022-04-08 华中农业大学 一种乙型脑炎病毒纳米颗粒疫苗及其制备方法和应用
US20230181717A1 (en) * 2021-12-14 2023-06-15 The Scripps Research Institute Methods and compositions related to hiv-1 nanoparticle vaccines with improved properties
CN116966289A (zh) * 2022-04-22 2023-10-31 本康生物制药(深圳)有限公司 纳米颗粒疫苗
WO2024006532A2 (en) * 2022-06-30 2024-01-04 La Jolla Institute For Immunology Kari nanoparticle
WO2024050452A2 (en) * 2022-08-30 2024-03-07 Administrators Of The Tulane Educational Fund Compositions and methods for raising immune responses to gram-negative bacteria
CN115894716B (zh) * 2022-11-23 2024-02-09 华中农业大学 一种重组融合蛋白纳米颗粒及其制备方法
WO2024123558A2 (en) * 2022-12-05 2024-06-13 The Scripps Research Institute Engineered lassa viral immunogens and vaccine compositions
AU2024280139A1 (en) 2023-05-30 2026-01-22 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine composition, method therefor and use thereof
AU2024287014A1 (en) 2023-06-07 2026-01-22 Sichuan Clover Biopharmaceuticals, Inc. Rsv vaccine composition, method and use thereof
CN121758569A (zh) * 2023-11-03 2026-03-31 广东蓝玉生物科技有限公司 非洲猪瘟病毒p15蛋白的免疫原性组合物及其应用
CN121758570A (zh) * 2023-11-03 2026-03-31 广东蓝玉生物科技有限公司 非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用
KR20260112755A (ko) 2023-11-13 2026-07-20 시추안 클로버 바이오파마슈티컬스, 인크. Rsv 백신 조성물, 방법 및 이의 용도
CN120923628A (zh) * 2024-05-09 2025-11-11 菲鹏生物股份有限公司 融合抗原及其应用
WO2026122753A1 (en) * 2024-12-04 2026-06-11 The Wistar Institute Of Anatomy And Biology Dna encoded nanoparticle vaccines against human papillomavirus, and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542194A (ja) 2005-04-06 2008-11-27 アイビーシー・ファーマシューティカルズ・インコーポレーテッド 多機能または多結合特異性を有する、改善した安定なテザー構造体の規定された組成物
JP2013503184A (ja) 2009-08-31 2013-01-31 アイビーシー ファーマスーティカルズ,インコーポレイテッド 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用
JP2017503857A (ja) 2014-01-09 2017-02-02 アルファ−オ ペプティデス アクツィエンゲゼルシャフト ワクチンプラットフォームとしてのフラジェリン含有タンパク質ナノ粒子
WO2017192434A1 (en) 2016-05-02 2017-11-09 The Scripps Research Institute Compositions and methods related to hiv-1 immunogens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
EP2073840A4 (en) 2006-10-23 2010-10-27 Progenics Pharm Inc MODIFIED GP140-HOLL-POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERS, COMPLEXES, AND ITS USES
WO2009109428A2 (en) 2008-02-01 2009-09-11 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
EP2391635B1 (en) * 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CA2851917A1 (en) * 2011-10-12 2013-04-18 Alpha-O Peptides Ag Self-assembling peptide nanoparticles as vaccines against infection with norovirus
EP2765138B1 (en) 2012-11-05 2018-01-10 International Aids Vaccine Initiative HIV-1 envelope glycoprotein
WO2014107744A1 (en) 2013-01-07 2014-07-10 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CA2902789A1 (en) * 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
JP7178344B2 (ja) 2016-09-15 2022-11-25 ヤンセン ファッシンズ アンド プリベンション ベーフェー 三量体安定化hivエンベロープタンパク質変異
EP3600402A1 (en) * 2017-03-23 2020-02-05 Alpha-O Peptides AG Self-assembling protein nanoparticles with built-in six-helix bundle proteins
JP2020515629A (ja) * 2017-04-04 2020-05-28 アヴィディア テクノロジーズ, インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
IL274130B2 (en) 2017-11-01 2025-08-01 Scripps Research Inst Novel scaffolded hiv-1 vaccine immunogens
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008542194A (ja) 2005-04-06 2008-11-27 アイビーシー・ファーマシューティカルズ・インコーポレーテッド 多機能または多結合特異性を有する、改善した安定なテザー構造体の規定された組成物
JP2013503184A (ja) 2009-08-31 2013-01-31 アイビーシー ファーマスーティカルズ,インコーポレイテッド 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用
JP2017503857A (ja) 2014-01-09 2017-02-02 アルファ−オ ペプティデス アクツィエンゲゼルシャフト ワクチンプラットフォームとしてのフラジェリン含有タンパク質ナノ粒子
WO2017192434A1 (en) 2016-05-02 2017-11-09 The Scripps Research Institute Compositions and methods related to hiv-1 immunogens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemistry & Biology,2003年,Vol. 10,p.723-731

Also Published As

Publication number Publication date
IL279351A (en) 2021-01-31
SG11202012313PA (en) 2021-01-28
KR20210021530A (ko) 2021-02-26
IL279351B2 (en) 2026-03-01
JP2021527077A (ja) 2021-10-11
CN112469661A (zh) 2021-03-09
US20200009244A1 (en) 2020-01-09
IL279351B1 (en) 2025-11-01
CA3103460A1 (en) 2019-12-19
US20220031835A1 (en) 2022-02-03
AU2019285048A1 (en) 2021-01-07
AU2019285048B2 (en) 2023-06-08
US11097002B2 (en) 2021-08-24
ZA202100032B (en) 2022-07-27
WO2019241483A1 (en) 2019-12-19
EA202092808A1 (ru) 2021-08-24
EP3807210A1 (en) 2021-04-21
CN112469661B (zh) 2024-04-26
US12447206B2 (en) 2025-10-21
EP3807210A4 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
US12447206B2 (en) Nanoparticle vaccines with novel structural components
US12448416B2 (en) Stabilized coronavirus spike (s) protein immunogens and related vaccines
AU2018358238B2 (en) Novel scaffolded HIV-1 vaccine immunogens
US11008368B2 (en) Engineered HCV E2 immunogens and related vaccine compositions
CA3207878A1 (en) Coronavirus spike protein designs, compositions and methods for their use
US11872277B2 (en) Compositions and methods related to ebolavirus vaccines
JP2023537518A5 (cg-RX-API-DMAC7.html)
EA046652B1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
JP2025539418A (ja) 新規ナノ粒子足場を含有するワクチン
KR20260066127A (ko) 신규한 c 형 간염 바이러스 (hepatitis c virus) 면역원들 및 관련 용도들
EA047661B1 (ru) Стабилизированные иммуногены коронавирусного шиповидного белка (s) и связанные вакцины

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240411

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240911

R150 Certificate of patent or registration of utility model

Ref document number: 7555826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150